Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global Markets

NEW YORK, Feb. 13, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global Markets
http://www.reportlinker.com/p02009162/Circulating-Tumor-Cell-CTC-Diagnostics-Technologies-and-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

STUDY GOALS AND OBJECTIVES

This report, PHM153A – Circulating Tumor Cell (CTC) Diagnostic: Technologies and Global Markets, gives market insight on monitoring tests used for cancer prognoses. The market is analyzed by cancer type: prostate, breast and colorectal. This report analyzes the circulating tumor cells market, including technologies as well as commercial perspective and describes the overall market size, industry growth rate and market trends. It gives a summary of the recent developments in the CTC market and includes detailed profiles of key players.
The report's focus is on circulating tumor cell testing and monitoring methods. The report also includes an overview on cancer, diagnostic strategies and treatment technologies. Important trends in the field of cancer research and development have been reviewed in this report, and sales forecasts by treatment and screening categories are provided from 2013 through 2018. Issues and trends addressed in this report are based on information from industry sources, regulatory and healthcare policies, demographics and other factors that directly affect the circulating tumor cell market.

REASONS FOR DOING THIS STUDY

This study was conducted to provide detailed information regarding new developments, testing and treatment options for cancer. There is an increasing need for new and innovative technologies. This industry is experiencing growth; the use of new diagnostic technologies for cancer has increased in the past few years.
This BCC Research study will increase the awareness of current and emerging technologies and diagnostics for cancer, especially prostate, breast and colorectal cancer.

INTENDED AUDIENCE

This report is an exhaustive study on the global cancer market with important incidence statistics and analysis of diagnostic technologies, latest trends, market structure, market size, key drug segments and trends in technology. This study contributes to the areas of market growth in circulating tumor cells and diagnostic strategies for metastatic cancer. This study will be of interest largely to the pharmaceutical and biotechnology industries, as well as to clinics, hospitals and research institutes. Also, this report may prove crucial for investment firms with involvement in this sector. The report shows tests currently being used for cancer diagnosis and prognosis, new developments, spending trends and revenue prospects for these technologies. The report provides market data for 2012 to 2018 and also covers commercial prospects for cancer diagnostic assays and tests currently in use and that are forecast for future use.

SCOPE OF THE STUDY

The scope of this study is clinical testing, prognostic and monitoring markets for CTCs in cancer. The report also includes the clinical segment, currently approved CTC tests and their markets, the regulatory environment, current technologies, new technologies, cancer incidence, market projections and market share along with the latest trends and new developments in this area. This report does not include the segment's research market including reagents, or any accessories used for CTC isolation or studies. The research segment of the market includes numerous competitors with different capabilities, developing and commercializing products such as CTC isolation devices and protocols, CTC characterization reagents, assay and instrumentation, and various identification technologies based on cell imaging. These market players include specialized or research-based companies that contribute considerably to the technological advancements in the field of CTC technologies. The data collected for the report is focused on breast, prostate and colorectal cancers for which clinical data and tests are available currently on the market. CTCs in other cancers are being researched and some are in clinical trials; these are not included within the scope of this report.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to paid and free databases. The base year of the report is 2012, with forecast data provided through 2018. Historical, base year and forecast data are provided for each market segment of this report.
The report provides a comprehensive review of cancer incidence and development of the disease, drugs currently being used and diagnostic technologies. The report also reviews technological developments, product innovations/introductions and recent strategic industry activity of major players across various product categories. Growth rates, global incidence and projections are determined through a compilation of data including past trends, future trends, demographics, incidence, mortality, products in R&D, current product growth, etc. Forecasts and projections were based on estimates such as the current trends, potential users, mergers and acquisitions, and market trends.
A comprehensive and exhaustive search of the literature on prostate cancer assay development and currently marketed products, global incidence and latest drug developments was conducted. These secondary sources include scientific–related journals and articles, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports and other publications. A patent search and analysis was also conducted. Some informal interviews were conducted with experts and personnel in this area at biotech and pharmaceutical companies. Other resources include academics, technology and consulting companies.

INFORMATION SOURCES

Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of products that include pharmaceutical and biotechnical industries, research institutes, etc. Data were gathered from various industry sources. BCC Research spoke with officials within the industry, consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.

ABOUT THE AUTHOR

Usha Nagavarapu, PhD, is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification including investigational new drug (IND)-enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. Usha has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden.

REPORT HIGHLIGHTS

The global market for circulating tumor cell (CTC) technology reached nearly $2.8 billion in 2012 and $3.7 billion in 2013. This market is estimated to reach nearly $8.9 billion by 2018, demonstrating a compound annual growth rate (CAGR) of 18.9% for the five-year period, 2013 to 2018.

This report provides:
• An overview of the global market for cancer diagnostics based on circulating tumor cells, which are used to increase understanding of tumor cell biology and metastatic cancer as a disease.
• Analyses of global market trends, with data from 2012 and 2013, and projections of compound annual growth rates for the period of 2013 to 2018.
• Discussion of the advantages and disadvantages of CTC enrichment techniques.
• Estimations of cancer incidence, cancer deaths, new cases by type in the United States, and breast cancer statistics and facts.
• Examination of growth opportunities and drivers in the CTC market and recent breakthroughs in research, along with a patent analysis.

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THIS STUDY 2
INTENDED AUDIENCE 2
SCOPE OF THE STUDY 3
METHODOLOGY 3
INFORMATION SOURCES 4
ABOUT THE AUTHOR 4
RELATED BCC RESEARCH REPORTS 4
BCC RESEARCH ONLINE SERVICES 4
DISCLAIMER 5

CHAPTER 2 SUMMARY 7

SUMMARY TABLE GLOBAL MARKET SALES AND FORECAST FOR CIRCULATING
TUMOR CELL TECHNOLOGY, THROUGH 2018 ($ MILLIONS) 8
SUMMARY FIGURE GLOBAL MARKET SALES AND FORECAST FOR CIRCULATING
TUMOR CELL TECHNOLOGY, 2012-2018 ($ MILLIONS) 8

CHAPTER 3 CIRCULATING TUMOR CELLS 10

CANCER 10
RECENT ADVANCES IN TECHNOLOGY 10
INVASIVE POWER 11
CIRCULATING TUMOR CELL 11
PHENOTYPIC CHARACTERISTICS 11
CTC CLUSTERS 12
CTC DETECTION 12
CANCER STEM CELLS (CSC) 13
TABLE 1 CATEGORIES OF STEM CELLS 14
TABLE 2 PRODUCT CATEGORIES 15
CIRCULATING TUMOR CELLS - POTENTIAL USES 15
TABLE 3 KEY FACTORS OF CTC'S 16
What Are Circulating Tumor Cells? 16
Biology and Characteristics of CTCs 17
TABLE 4 CIRCULATING TUMOR CELLS - FEATURES 18

PROLIFERATIVE ACTIVITY 18
EPITHELIAL MARKER GENES ON CIRCULATING TUMOR CELLS 19
CTCs as Biomarkers 20
Biomarker Qualification Program 21
Epithelial to Mesenchymal Transition 21
CIRCULATING TUMOR CELLS AND STEM CELL-LIKE PHENOTYPE 22
CTCS AND PRIMARY TUMOR CELLS: COMPARISON 22
METASTASIS 23
The Metastatic Process 23
FUTURE DIRECTIONS 24
TABLE 5 METASTATIC CASCADE 24
METASTATIC DEVELOPMENT IN CANCER PATIENTS 25
CIRCULATING TUMOR CELL MIGRATION 25
IMPORTANT MARKERS OF DISTANT METASTASIS 25
CIRCULATING TUMOR CELL DETECTION 25
TABLE 6 EPCAM-BASED ASSAYS 26
CHALLENGES FOR DETECTION 26
THE CLINICAL APPLICATION OF CIRCULATING TUMOR DNA 27
CIRCULATING TUMOR CELLS AS PREDICTOR OF RESPONSE TO THERAPY 27
MEASUREMENT OF CTCS - APPLICATIONS 28
CONCLUSION 28
TABLE 7 CTC DETECTION - ADVANTAGES 29

CHAPTER 4 INCIDENCE OF CANCER 31

WORLDWIDE GROWTH IN THE INCIDENCE OF CANCER 31
TABLE 8 CANCER - KEY FACTS 32
CAUSES OF CANCER 32
TABLE 9 CANCER CAUSES 33
RISK FACTORS FOR CANCERS 33
BURDEN OF CANCER 33
AVOIDING RISK FACTORS 33

TABLE 10 CANCER CAUSING FACTORS 34
Prevention Strategies 34
EARLY DETECTION 34
Early Diagnosis 34
Screening 34
TABLE 11 CANCER SCREENING METHODS 35
TREATMENT 35
Treatment of Early-Detectable Cancers 35
Treatment of Other Cancers with Potential for Cure 35
PALLIATIVE CARE 35
Palliative Care Strategies 36
WORLD HEALTH ORGANIZATION RESPONSE 36
TABLE 12 NONCOMMUNICABLE DISEASES ACTION PLAN 36
WORLD CANCER STATISTICS 36
TABLE 13 GLOBAL CANCER INCIDENCE ESTIMATES, 2008 AND 2030 (MILLIONS) 37
FIGURE 1 GLOBAL CANCER INCIDENCE ESTIMATES, 2008 AND 2030 (MILLIONS) 37
TABLE 14 ESTIMATED GLOBAL CANCER INCIDENCE, 2008 (THOUSANDS) 38
CANCER AND THE GLOBAL IMPACT 38
Prevalence 39
Global Patterns 39
THE FUTURE OF CANCER 40

TABLE 15 INCREASE IN CANCER BURDEN - FACTORS 41
Common Types of Cancer 42
TABLE 16 THE MAIN TYPES OF CANCER AND ASSOCIATED MORTALITY 43
TABLE 17 GENERAL GLOBAL CANCER INCIDENCE BY TYPE 43
TABLE 18 GLOBAL INCIDENCE OF CANCER BY TYPE, 2008 (THOUSANDS/%) 44
Global Incidence in Men 45
TABLE 19 CANCER INCIDENCE IN MEN, 2008 (THOUSANDS/%) 45
Global Incidence in Women 46
TABLE 20 CANCER INCIDENCE IN WOMEN, 2008 (THOUSANDS/%) 46
Developed Countries 47
TABLE 21 GLOBAL INCIDENCE OF CANCER IN DEVELOPED COUNTRIES
AGE-STANDARDIZED RATE PER 100,000, 2008 47
Men 48
TABLE 22 GLOBAL INCIDENCE OF CANCER IN MEN - DEVELOPED COUNTRIES
AGE-STANDARDIZED RATE PER 100,000 (WORLD), 2008 48
Incidence in Women 49
TABLE 23 GLOBAL INCIDENCE OF CANCER IN WOMEN - DEVELOPED COUNTRIES
AGE-STANDARDIZED RATE PER 100,000 (WORLD), 2008 49
UNITED STATES CANCER INCIDENCE 50
TABLE 24 UNITED STATES - COMMON TYPE OF CANCER ESTIMATES, 2013 50
FIGURE 2 UNITED STATES - COMMON TYPE OF CANCER ESTIMATES, 2013 50
BREAST CANCER 51
TABLE 25 GLOBAL BREAST CANCER FACTS 51
TABLE 26 BREAST CANCER IN THE UNITED STATES 52
COLORECTAL CANCER 53
TABLE 27 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF COLORECTAL
CANCER IN MEN, 2008 54

TABLE 28 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF COLORECTAL
CANCER IN WOMEN, 2008 55
U.S. Incidence 55
TABLE 29 UNITED STATES - COLORECTAL CANCER INCIDENCE ESTIMATES, 2013 55
FIGURE 3 UNITED STATES - COLORECTAL CANCER INCIDENCE ESTIMATES, 2013 56
PROSTATE CANCER 56
TABLE 30 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF PROSTATE
CANCER, 2008 56
Westernization Trends 57
TABLE 31 PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008
(THOUSANDS) 58
FIGURE 4 PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008
(THOUSANDS) 58
Prostate Cancer Mortality 60
TABLE 32 GLOBAL ESTIMATED PROSTATE CANCER DEATHS AND
AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008 60
FIGURE 5 GLOBAL ESTIMATED PROSTATE CANCER DEATHS AND
AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008 61
Prostate Cancer a Burden Globally 61
TABLE 33 GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER, 2008–2030
(NUMBER) 62

FIGURE 6 GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER 2008-2030
(NUMBER) 62
Prostate Cancer and the U.S. 63
TABLE 34 PROSTATE CANCER CASES AND DEATHS IN THE U.S. 2008-2011
(NUMBER) 63
FIGURE 7 PROSTATE CANCER CASES AND DEATHS IN THE U.S., 2008-2011
(NUMBER) 63
TABLE 35 ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012-2030
(NUMBER) 64
FIGURE 8 ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012-2030
(NUMBER) 64
TABLE 36 PROSTATE CANCER INCIDENCE RATES IN THE U.S. BY RACE, 2005-2009
(PER 100,000 MEN) 65
TABLE 37 ESTIMATED PROSTATE CANCER CASES IN THE U S., 2020 AND 2030
(NUMBER) 65
FIGURE 9 ESTIMATED PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030
(NUMBER) 66
Prostate Cancer Mortality Rates in the U.S. 66
TABLE 38 MORTALITY RATES BY RACE IN U.S., 2005-2009 66
Prostate Cancer in Canada 67
TABLE 39 ESTIMATED PROSTATE CANCER IN CANADA, 2012 (NUMBER) 67
Prostate Cancer in Europe 67
TABLE 40 EUROPEAN (EU27 COUNTRIES) ESTIMATED PROSTATE CANCER
MORTALITY - AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATION,
2008
68
FIGURE 10 EUROPEAN (EU27 COUNTRIES) ESTIMATED PROSTATE CANCER
MORTALITY - AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS,
2008
68
Prostate Cancer in the United Kingdom 69
TABLE 41 PROSTATE CANCER DEATHS IN THE U.K., 2010 (RATE PER 100,000
POPULATION) 70
FIGURE 11 PROSTATE CANCER DEATHS IN THE U.K., 2010 (RATE PER 100,000
POPULATION) 71
Prostate Cancer in Asia 71
CONCLUSIONS 72

CHAPTER 5 TECHNOLOGIES 74

FINDING CIRCULATING TUMOR CELLS 74
TABLE 42 POTENTIAL APPLICATIONS OF CTC-BASED DIAGNOSTICS 74
CURRENT CTC DETECTION AND ISOLATION METHODS 75
NEW TECHNOLOGIES FOR THE DETECTION 75
CANCER PROGNOSIS 76
Carcinoma - CTC and the Metastatic Cascade 77
How many CTCs? 77
The Biological Characteristics of CTC 77
TABLE 43 CLINICAL RELEVANCE OF CTC 78
Cancer Dissemination 78
CTC DETECTION TECHNIQUES - REQUIREMENTS 78
TABLE 44 CTC ENRICHMENT METHODS 78
ENRICHMENT METHODS 79
TABLE 45 TECHNIQUES USED FOR CIRCULATING TUMOR CELL (CTC) ENRICHMENT 80
Morphology-Based Enrichment Methods 80
Cell Separation Based on Density Gradient Centrifugation 80
Size-Based Cell Enrichment by Filtration 81
Immunomagnetic Separation Techniques 81
The RosetteSep-Applied Imaging Rare Event (RARE) Method 82
MagSweeper 83
DETECTION METHODS 83
TABLE 46 TECHNIQUES USED FOR CIRCULATING TUMOR CELL (CTC) ANALYSIS 84
Immunocytochemical Approaches 84
Fiber-Optic Array Scanning Technology 85
Laser Scanning Cytometer 85
Multiphoton Intravital Flow Cytometry 85

COMBINED ENRICHMENT AND DETECTION METHODS 85
TABLE 47 ENUMERATION TECHNIQUES 86
CellSearch System 86
Microfluidic Devices 87
Microfluidic Chips 87
EPISPOT 88
AdnaTest 88
TelomeScan 89
CTC Chip 89
TABLE 48 FUNCTIONAL ASSAYS 90
NUCLEIC ACID-BASED METHODS 91
Limitations 92
Flow Cytometry 92
Image-Based Approaches 93
Reverse-Transcriptase PCR 93
CLINICAL TESTING 94
CTC Analysis in Cancer Patients 94
CTC Analysis in Patients with Metastatic Disease 95
SUMMARY 96
TABLE 49 KEY FACTS ABOUT CIRCULATING TUMOR CELLS 97
NEW EMERGING TECHNOLOGIES 97
TABLE 50 MICRO-COUNT FEATURES A NEW TECHNOLOGY 98
Herringbone-Chip (HB-Chip) 98
Future Directions 99

CHAPTER 6 CIRCULATING TUMOR CELLS AND CANCER DIAGNOSTICS 101

TABLE 51 CTC ASSAY PRE-ANALYTICAL VALIDATION CONSIDERATIONS 102
TABLE 52 CTC ASSAY ANALYTICAL VALIDATION CONSIDERATIONS 102
TABLE 53 CTC ASSAY POST-ANALYTICAL VALIDATION CONSIDERATIONS 103
USE OF CTC'S FOR DIAGNOSIS 103
TABLE 54 CURRENT ENRICHMENT ASSAYS FOR CTCS 105
TABLE 55 CTC ENUMERATION ASSAYS 108
CURRENT METHODS AND APPLICATIONS 110
CTC Chip 110
TABLE 56 CHARACTERIZATION ASSAYS FOR CTCS 111
IVD Diagnostics 112
TABLE 57 KEY FEATURES-IVD CTC TESTS 112
TABLE 58 TUMOR TYPES: PROJECTED NEW CASES AND ESTIMATED DEATHS, 2010 112
FIGURE 12 TUMOR TYPES - PROJECTED NEW CASES AND ESTIMATED DEATHS,
2010 113
IVDiagnostics Customized Aptamer Selection Service 114

IVDiagnostics CTC Capture 114
IVDiagnostics CTC Human Genetics 114
Biocept 114
CIRCULATING TUMOR CELLS IN PROSTATE CANCER: CASE STUDIES 114
TABLE 59 PROSTATE CANCER DIAGNOSIS AND ROLE OF CTC'S 115
CTC IN COMPANION DIAGNOSTICS 115
TABLE 60 CURRENT DIAGNOSTIC METHODS 115
ApoCell 116
TABLE 61 APOSTREAM KEY FEATURES 116
ApoStream CTC Imaging 116
Clarient Launches Biocept's OncoCEE-BR Test 117
Canopus Bioscience 117
TABLE 62 CANOPUS BIOSCIENCE TECHNOLOGY - BENEFITS 118
Ikonisys 118
TABLE 63 CELLOPTICS' CANCER APPLICATION 118
Technique 119
TABLE 64 CELLOPTICS' KEY FEATURES - ENRICHMENT 119
TABLE 65 CELLOPTICS' KEY FEATURES - LABELING 119
TABLE 66 CELLOPTICS' KEY FEATURES - DETECTION 120
RAREcells Diagnostics 120
TABLE 67 ISET TEST - SPECIFICATIONS 120
NEWER TECHNOLOGIES IN DEVELOPMENT 121
OriGene Technologies 121
Protein Microarray and Its Application 121
Viator Technologies 121
Photoacoustic Detection and Capture of CTCs 121
Micro Technologies 121
Interrogate Signaling in Single Cells 121

NanoVelcro 122
Embedded Microchips 122
MOLECULAR ANALYSES OF CTC 122
The Ephesia Magnetic Arrays Technology 122
New "Biopsy in a Blood Test" 122
CONCLUSIONS 124

CHAPTER 7 CTCS IN CLINICAL TRIALS 126

CTC DIAGNOSTICS 126
CIRCULATING TUMOR CELL TECHNOLOGY 126
POTENTIAL THERAPEUTIC USES OF CIRCULATING TUMOR CELLS 127
CHALLENGES IN THE DETECTION OF CIRCULATING TUMOR CELLS 128
CTC'S AS CLINICAL BIOMARKERS 129
PCR-BASED MARKERS 130
Carcinoma Cells 130
CIRCULATING TUMOR CELLS IN CANCER - CURRENT STATUS 130
Breast Cancer 130
STIC CTC METABREAST (France) 131
SWOG 0500 (USA) 132
CirCe01 (France) 132
Treat CTC (Europe) 133
DETECT III (Germany) 134
PROGNOSTIC AND PREDICTIVE VALUE OF CIRCULATING TUMOR CELLS
(CTC'S) 135
Breast Cancer 135

Pancreatic Cancer 136
Lung Cancer 137
CTC'S IN CLINICAL CANCER MANAGEMENT 137
TABLE 68 CTC TECHNOLOGIES FOR CLINICAL MANAGEMENT 137
Clinical Impact of CTCs 138
EXISTING TECHNOLOGIES IN CLINICAL TRIALS 138
Cell Search and AdnaTest - Comparision 138
Size- and Biomechanical Properties-Based Isolation 140
CLINICAL STUDIES USING CELLSEARCH TECHNOLOGY 141
TABLE 69 CTC TECHNOLOGIES FOR CLINICAL MANAGEMENT 142
APPROVALS 142
RECENT STUDIES 143
Tumor Cell (CTC) Enumeration Using Cellsearch 143
CELLSEARCH IN CHINA 144
VERIDEX AND MASSACHUSETTS GENERAL HOSPITAL COLLABORATION 145
POSSIBLE USE OF CTC'S AND DTC'S AS NEW BIOMARKERS 146
EPISPOT 147
CLINCIAL APPLICATIONS 147
TABLE 70 EPISPOT: CLINICAL TRIALS FOR DETECTION OF CTC'S 148
Descriptions of Clinical Trials 148
NCT01402154 Trial 148
NCT01558349 Trial 148
NCT01596790 Trial 148
TABLE 71 OUTCOME MEASUREMENTS NCT01596790 TRIAL 149
ApoCell 149
ApoCell and Transgenomic Present Results of Lung Cancer
Research Study 149
ApoCell's CTC Capture Technology Detects and Recovers Deadly
Liver Cancer Cells 150
Nektar's Ongoing Phase 3 BEACON Study 150
APPLICATIONS 151
Application of iCTC Detection and Culture in Personalized Cancer
Management 151
Stony Brook University Medical Center 151
Microfluidic Sorting of Blood Cells for Cellular and Molecular Analysis 152
Cancer Sample Preparation with Micromachined Magnetic Sifter and

Nanoparticles 152
Stanford Center for Magnetic Nanotechnology 152
The Scripps Research Institute: The Fluid Phase of Solid Tumors 152
ApoCell - Utilization of Dielectrophoresis for Antigen-Independent CTC
Capture Allows for Detection of Heterogeneous Tumor Cell
Populations
152
APPLICATION OF CTC TECHNOLOGIES TO CLINICAL TESTING 153
CTC TECHNOLOGIES FOR CLINICAL DEVELOPMENT 154
Practical Application 154
TABLE 72 CTC ASSAY CLINICAL READINESS EVALUATION 155
TABLE 73 CTC ASSAY ANALYTICAL VALIDATION CONSIDERATIONS 156
STANDARD RECOMMENDATIONS 156
Specificity of a CTC Assay 157
Clinical Trial Design Considerations 158
TABLE 74 CTC QUALIFICATION STUDIES 158
SWOG S0500 Trial 159
Study Strategy and Process 159
CTC NUMBER AS A PROGNOSTIC BIOMARKER 161
Breast Cancer 161
Metastatic Castrate-resistant Prostate Cancer 161
Colorectal Cancer 162
Lung Cancer 162
PROGNOSTIC STUDIES 162
CTC'S AS A SURROGATE RESPONSE BIOMARKER 163
CTC'S AS A REAL-TIME BIOPSY 163
CTC CHIP TECHNOLOGY AND EGFR MUTATION ANALYSIS 164
CTC CHARACTERIZATION AFTER ENRICHMENT USING THE CELLSEARCH
PLATFORM 164
FINAL REMARKS 165

CHAPTER 8 CIRCULATING TUMOR CELL MARKET 167

THE INVASIVE CANCER! 167
TABLE 75 GLOBAL CANCER INCIDENCE - ESTIMATES, 2008-2030 (MILLIONS) 167
FIGURE 13 GLOBAL CANCER INCIDENCE - ESTIMATES, 2008-2030 (MILLIONS) 167
CANCER SURVIVAL 168
TABLE 76 GLOBAL CANCER SURVIVORS, 2008 (MILLIONS) 169
FIGURE 14 GLOBAL CANCER SURVIVORS 2008 (MILLIONS) 169
TABLE 77 UNITED STATES CANCER SURVIVORS, 2008-2022 (MILLIONS) 169
TABLE 78 MALE CANCER SURVIVORS (%) 170
TABLE 79 FEMALE CANCER SURVIVORS (%) 170
GLOBAL ANNUAL ONCOLOGY MARKET 171
CANCER THERAPY 172
TABLE 80 MAJOR PLAYERS 172
TABLE 81 GLOBAL CANCER DRUG MARKET SALES AND FORECAST, THROUGH 2018
($ MILLIONS) 173
FIGURE 15 GLOBAL CANCER DRUG MARKET SALES AND FORECAST, 2012-2018 ($
MILLIONS) 173
AGING AND CANCER 174
CANCER DRUG PIPELINE 174
TABLE 82 DRUGS APPROVED IN 2013 175
CANCER COSTS IN THE U.S. 175
TABLE 83 CANCER FORECAST IN U.S., 2020 - KEY FACTS 176
TABLE 84 CANCER CARE COST IN U.S., 2010 AND 2020 ($ BILLIONS) 177
BREAST CANCER 177
Treatment and Survival 177
Common Side Effects of Treatment 178

COLON AND RECTUM 179
Treatment and Survival 179
Common Side Effects of Treatment 179
PROSTATE 180
Treatment and Survival 180
Common Side Effects of Treatment 180
CHEMOTHERAPY MARKET 180
CANCER TESTING MARKET 181
TABLE 85 GLOBAL IN VITRO DIAGNOSTICS MARKET SALES AND FORECAST
THROUGH 2018 ($ MILLIONS) 181
FIGURE 16 GLOBAL IN VITRO DIAGNOSTICS MARKET SALES AND FORECAST
2012-2018 ($ MILLIONS) 181
TABLE 86 CANCER TESTING MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 183
FIGURE 17 CANCER TESTING MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 183
TABLE 87 KEY PLAYERS 184
IVD Market in China 185
CURRENT CANCER DIAGNOSTIC TESTS 186
Cancer Testing in Developing Nations 186
New Opportunities 186
TABLE 88 SIGNIFICANT DEVELOPMENTS IN CANCER FOLLOW-UP 187
A UNIVERSAL TUMOR TEST- IS IT POSSIBLE? 187
TABLE 89 CANCER TESTS AND LIMITATIONS - THE CASE AGAINST DEVELOPMENT
OF A UNIVERSAL TEST 188
CANCER BIOMARKER TESTING MARKET 188
TABLE 90 GLOBAL BIOMARKER MARKET AND FORECAST, THROUGH 2018 ($
MILLIONS) 188
FIGURE 18 GLOBAL BIOMARKER MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 188
TABLE 91 THE KEY PLAYERS 189
TABLE 92 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, THROUGH
2018 ($ MILLIONS) 190

FIGURE 19 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, 2012-2018
($ MILLIONS) 190
MOLECULAR DIAGNOSTICS 191
TABLE 93 MOLECULAR DIAGNOSTICS MARKET AND FORECAST, THROUGH 2018 ($
MILLIONS) 191
FIGURE 20 MOLECULAR DIAGNOSTICS MARKET AND FORECAST, 2012-2018 ($
MILLIONS) 191
CANCER BIOMARKER TESTS 192
CANCER DISEASE MANAGEMENT 192
PERSONALIZED CANCER TESTING 192
Cancer Testing Competitors 192
CIRCULATING TUMOR CELL MARKET - A NEW APPROACH 193
TABLE 94 CTC'S - DIFFERENTIATING FEATURES 194
CTCs Advantages 194
THE CLINICAL DIAGNOSTICS MARKET 195
Market Opportunities 195
TABLE 95 STEM CELL MARKET OVERVIEW 196
TABLE 96 KEY COMPANIES SELLING STEM CELL RESEARCH PRODUCTS 196
CTC Testing 197
TABLE 97 CTC COMPANIES WITH PROMISING PRODUCTS 197
CellSearch CTC test 198
TABLE 98 CLINICAL USE OF CELLSEARCH SYSTEM 198
AdnaTest 198
CURRENT STATUS OF THE MARKET 198
TABLE 99 PRICING (DOLLARS) 199
TABLE 100 CELLSEARCH KIT 199
Updated Coding and Payment for Circulating Tumor Cell Testing 200
Global Market for Circulating Cancer Cells (CTCs) 200
TABLE 101 GLOBAL CIRCULATING TUMOR CELL TESTING MARKET SALES AND
FORECAST BY REGION, THROUGH 2018 ($ MILLIONS) 201
FIGURE 21 GLOBAL CIRCULATING TUMOR CELL TESTING MARKET SALES AND
FORECAST BY REGION, 2012-2018 ($ MILLIONS) 201
TABLE 102 GLOBAL CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER -
SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS) 202
FIGURE 22 GLOBAL CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER -
SALES AND FORECAST BY REGION, 2012-2018 ($ MILLIONS) 203

TABLE 103 GLOBAL CIRCULATING TUMOR CELL MARKET FOR BREAST CANCER -
SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS) 204
FIGURE 23 GLOBAL CIRCULATING TUMOR CELL MARKET FOR BREAST CANCER -
SALES AND FORECAST BY REGION, 2012-2018 ($ MILLIONS) 204
TABLE 104 GLOBAL CIRCULATING TUMOR CELL MARKET FOR COLORECTAL
CANCER - SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS) 205
FIGURE 24 GLOBAL CIRCULATING TUMOR CELL MARKET FOR COLORECTAL
CANCER -SALES AND FORECAST BY REGION, 2012-2018 ($ MILLIONS) 205
United States Market for Circulating Cancer Cells (CTCs) 206
TABLE 105 U.S. CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER -
SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 207
FIGURE 25 U.S. CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER -
SALES AND FORECAST, 2012-2018 ($ MILLIONS) 207
TIMELINE 207
TABLE 106 U.S. CIRCULATING TUMOR CELL MARKET - BY INDICATION, SALES AND
FORECAST, THROUGH 2018 ($ MILLIONS) 208
FIGURE 26 U.S. CIRCULATING TUMOR CELL MARKET - BY INDICATION SALES AND
FORECAST, 2012-2018 ($ MILLIONS) 208
Europe - Market for Circulating Cancer Cells (CTCs) 208
TABLE 107 EUROPEAN CIRCULATING TUMOR CELL MARKET SALES AND FORECAST,
THROUGH 2018 ($ MILLIONS) 209
FIGURE 27 EUROPEAN CIRCULATING TUMOR CELL MARKET SALES AND FORECAST,
2012-2018 ($ MILLIONS) 209
TABLE 108 EUROPEAN CIRCULATING TUMOR CELL MARKET BY CANCER TYPE -
SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 210
Rest of World Market for Circulating Cancer Cells (CTCs) 210
TABLE 109 REST OF WORLD CIRCULATING TUMOR CELL MARKET SALES AND
FORECAST, THROUGH 2018 ($ MILLIONS) 210
FIGURE 28 REST OF WORLD CIRCULATING TUMOR CELL MARKET SALES AND
FORECAST, 2012-2018 ($ MILLIONS) 211
Canada 211
TABLE 110 REST OF WORLD CIRCULATING TUMOR CELL MARKET BY CANCER TYPE
- SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 212
FIGURE 29 REST OF WORLD CIRCULATING TUMOR CELL MARKET BY CANCER TYPE
- SALES AND FORECAST, 2012-2018 ($ MILLIONS) 212
ASIA-PACIFIC SOLID TUMORS MARKET 212
FUTURE AND NEXT STEPS 213

CHAPTER 9 PATENTS 216

TABLE 111 CIRCULATING TUMOR CELL ASSAY CHARACTERISTICS 216
KEY PATENTS 216
TABLE 112 CTC PATENTS 217
VERIDEX 218
EpCAM Based Enrichment Using Magnetic Beads 218
MAGSWEEPER 218
EpCAM Based Magnetic Beads 218
SCRIPPS RESEARCH INSTITUTE (EPIC SCIENCES) 219
HD-CTC Technology 219
CELLPOINT DIAGNOSTICS 219
ON-Q-ITY 219
BIOFLUIDICA 219
ADNAGEN 220
Multiple Antibodies on Magnetic Beads 220
FILTINI 220

3D Parylene Membrane Filter for Isolation of CTC 220
IKONISYS 220
AVIVA BIOSCIENCES 221
Methods, Compositions, and Automated Systems for Separating Rare
Cells 221
TABLE 113 KEY PATENTS BY AVIVA BIOSCIENCES 221
HARVARD UNIVERSITY - MEHMET TONER, PHD 221
Microposts Coated with EpCAM 221
CELLECTIVE DX 222
Materal Displacement Obstacle Chip 222
JOHNS HOPKINS UNIVERSITY 222
Antibody-Coated Microfluidic Chip and Quantum Dots-Based Imaging 222
MEDICAL DISCOVERY PARTNERS 222
RBC Agglutination Followed by Filtration 222
CYNVENIO BIOSYSTEMS 222
Microfluidic Sheath Flow for Cell Isolation 222
SCREENCELL 223
BIOCEPT 223
Recovery of Rare Cells Using a Microchannel Apparatus with
Patterned Posts 223
CANOPUS BIOSCIENCE 223
Enrichment Technology Is Now Protected by Key Patents 223
ADVANCED CELL DIAGNOSTICS 224

CHAPTER 10 SELECTED COMPANY PROFILES 226

COMPANIES 226
KEY PLAYERS 226
TABLE 114 COMMERCIAL CIRCULATING TUMOR CELL TECHNOLOGY PLATFORMS 226
KEY COMPANY PROFILES 227
ADNAGEN 227
ADVANCED CELL DIAGNOSTICS 227
APOCELL 228
AVIVA BIOSCIENCES 228
BIOCEP LTD. 229
BIOCEPT INC. 229
BIOFLUIDICA MICROTECHNOLOGIES LLC 230
CANOPUS BIOSCIENCES 230
CELLTRAFIX INC. 230
CELULA 231

CLEARBRIDGE BIOMEDICS 231
CREATV MICROTECH INC 232
CYNVENIO BIOSYSTEMS, INC. 232
EPIC BIOSCIENCES 232
FILTINI INC. 233
FLUXION BIOSCIENCES 233
GREINER BIO-ONE GMBH 233
IKONISYS INC. 234
IVDIAGNOSTICS INC. 234
JANSSEN DIAGNOSTICS 234
MILTENYI BIOTECH 234
NANOSTRING TECHNOLOGIES INC. 235
NATURAL NANO INC. 235
ONCO VISTA 235
ON-Q-ITY 235
RARECELLS 236
SCREENCELL 236
SILICON BIOSYSTEMS USA 237
STEMCELL TECHNOLOGIES 237
SYNERGEX CORPORATION 237
SYSMEX CORPORATION 238
VERIDEX, LLC 238
VITATEX INC. 239

CHAPTER 11 REFERENCES 241

LIST OF TABLES

SUMMARY TABLE GLOBAL MARKET SALES AND FORECAST FOR CIRCULATING
TUMOR CELL TECHNOLOGY, THROUGH 2018 ($ MILLIONS) 8
TABLE 1 CATEGORIES OF STEM CELLS 14
TABLE 2 PRODUCT CATEGORIES 15
TABLE 3 KEY FACTORS OF CTC'S 16
TABLE 4 CIRCULATING TUMOR CELLS - FEATURES 18
TABLE 5 METASTATIC CASCADE 24
TABLE 6 EPCAM-BASED ASSAYS 26
TABLE 7 CTC DETECTION - ADVANTAGES 29
TABLE 8 CANCER - KEY FACTS 32
TABLE 9 CANCER CAUSES 33
TABLE 10 CANCER CAUSING FACTORS 34
TABLE 11 CANCER SCREENING METHODS 35
TABLE 12 NONCOMMUNICABLE DISEASES ACTION PLAN 36
TABLE 13 GLOBAL CANCER INCIDENCE ESTIMATES, 2008 AND 2030 (MILLIONS) 37
TABLE 14 ESTIMATED GLOBAL CANCER INCIDENCE, 2008 (THOUSANDS) 38
TABLE 15 INCREASE IN CANCER BURDEN - FACTORS 41
TABLE 16 THE MAIN TYPES OF CANCER AND ASSOCIATED MORTALITY 43
TABLE 17 GENERAL GLOBAL CANCER INCIDENCE BY TYPE 43
TABLE 18 GLOBAL INCIDENCE OF CANCER BY TYPE, 2008 (THOUSANDS/%) 44
TABLE 19 CANCER INCIDENCE IN MEN, 2008 (THOUSANDS/%) 45
TABLE 20 CANCER INCIDENCE IN WOMEN, 2008 (THOUSANDS/%) 46
TABLE 21 GLOBAL INCIDENCE OF CANCER IN DEVELOPED COUNTRIES
AGE-STANDARDIZED RATE PER 100,000, 2008 47
TABLE 22 GLOBAL INCIDENCE OF CANCER IN MEN - DEVELOPED COUNTRIES
AGE-STANDARDIZED RATE PER 100,000 (WORLD), 2008 48
TABLE 23 GLOBAL INCIDENCE OF CANCER IN WOMEN - DEVELOPED COUNTRIES
AGE-STANDARDIZED RATE PER 100,000 (WORLD), 2008 49
TABLE 24 UNITED STATES - COMMON TYPE OF CANCER ESTIMATES, 2013 50
TABLE 25 GLOBAL BREAST CANCER FACTS 51

TABLE 26 BREAST CANCER IN THE UNITED STATES 52
TABLE 27 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF COLORECTAL
CANCER IN MEN, 2008 54
TABLE 28 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF COLORECTAL
CANCER IN WOMEN, 2008 55
TABLE 29 UNITED STATES - COLORECTAL CANCER INCIDENCE ESTIMATES, 2013 55
TABLE 30 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF PROSTATE CANCER,
2008 56
TABLE 31 PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008
(THOUSANDS) 58
TABLE 32 GLOBAL ESTIMATED PROSTATE CANCER DEATHS AND
AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008 60
TABLE 33 GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER, 2008–2030
(NUMBER) 62
TABLE 34 PROSTATE CANCER CASES AND DEATHS IN THE U.S. 2008-2011 (NUMBER) 63
TABLE 35 ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012-2030
(NUMBER) 64
TABLE 36 PROSTATE CANCER INCIDENCE RATES IN THE U.S. BY RACE, 2005-2009
(PER 100,000 MEN) 65
TABLE 37 ESTIMATED PROSTATE CANCER CASES IN THE U S., 2020 AND 2030
(NUMBER) 65
TABLE 38 MORTALITY RATES BY RACE IN U.S., 2005-2009 66
TABLE 39 ESTIMATED PROSTATE CANCER IN CANADA, 2012 (NUMBER) 67
TABLE 40 EUROPEAN (EU27 COUNTRIES) ESTIMATED PROSTATE CANCER
MORTALITY - AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATION,
2008
68
TABLE 41 PROSTATE CANCER DEATHS IN THE U.K., 2010 (RATE PER 100,000
POPULATION) 70
TABLE 42 POTENTIAL APPLICATIONS OF CTC-BASED DIAGNOSTICS 74
TABLE 43 CLINICAL RELEVANCE OF CTC 78
TABLE 44 CTC ENRICHMENT METHODS 78
TABLE 45 TECHNIQUES USED FOR CIRCULATING TUMOR CELL (CTC) ENRICHMENT 80
TABLE 46 TECHNIQUES USED FOR CIRCULATING TUMOR CELL (CTC) ANALYSIS 84
TABLE 47 ENUMERATION TECHNIQUES 86
TABLE 48 FUNCTIONAL ASSAYS 90
TABLE 49 KEY FACTS ABOUT CIRCULATING TUMOR CELLS 97

TABLE 50 MICRO-COUNT FEATURES A NEW TECHNOLOGY 98
TABLE 51 CTC ASSAY PRE-ANALYTICAL VALIDATION CONSIDERATIONS 102
TABLE 52 CTC ASSAY ANALYTICAL VALIDATION CONSIDERATIONS 102
TABLE 53 CTC ASSAY POST-ANALYTICAL VALIDATION CONSIDERATIONS 103
TABLE 54 CURRENT ENRICHMENT ASSAYS FOR CTCS 105
TABLE 55 CTC ENUMERATION ASSAYS 108
TABLE 56 CHARACTERIZATION ASSAYS FOR CTCS 111
TABLE 57 KEY FEATURES-IVD CTC TESTS 112
TABLE 58 TUMOR TYPES: PROJECTED NEW CASES AND ESTIMATED DEATHS, 2010 112
TABLE 59 PROSTATE CANCER DIAGNOSIS AND ROLE OF CTC'S 115
TABLE 60 CURRENT DIAGNOSTIC METHODS 115
TABLE 61 APOSTREAM KEY FEATURES 116
TABLE 62 CANOPUS BIOSCIENCE TECHNOLOGY - BENEFITS 118
TABLE 63 CELLOPTICS' CANCER APPLICATION 118
TABLE 64 CELLOPTICS' KEY FEATURES - ENRICHMENT 119
TABLE 65 CELLOPTICS' KEY FEATURES - LABELING 119
TABLE 66 CELLOPTICS' KEY FEATURES - DETECTION 120
TABLE 67 ISET TEST - SPECIFICATIONS 120
TABLE 68 CTC TECHNOLOGIES FOR CLINICAL MANAGEMENT 137
TABLE 69 CTC TECHNOLOGIES FOR CLINICAL MANAGEMENT 142
TABLE 70 EPISPOT: CLINICAL TRIALS FOR DETECTION OF CTC'S 148
TABLE 71 OUTCOME MEASUREMENTS NCT01596790 TRIAL 149
TABLE 72 CTC ASSAY CLINICAL READINESS EVALUATION 155
TABLE 73 CTC ASSAY ANALYTICAL VALIDATION CONSIDERATIONS 156
TABLE 74 CTC QUALIFICATION STUDIES 158
TABLE 75 GLOBAL CANCER INCIDENCE - ESTIMATES, 2008-2030 (MILLIONS) 167
TABLE 76 GLOBAL CANCER SURVIVORS, 2008 (MILLIONS) 169
TABLE 77 UNITED STATES CANCER SURVIVORS, 2008-2022 (MILLIONS) 169
TABLE 78 MALE CANCER SURVIVORS (%) 170
TABLE 79 FEMALE CANCER SURVIVORS (%) 170

TABLE 80 MAJOR PLAYERS 172
TABLE 81 GLOBAL CANCER DRUG MARKET SALES AND FORECAST, THROUGH 2018
($ MILLIONS) 173
TABLE 82 DRUGS APPROVED IN 2013 175
TABLE 83 CANCER FORECAST IN U.S., 2020 - KEY FACTS 176
TABLE 84 CANCER CARE COST IN U.S., 2010 AND 2020 ($ BILLIONS) 177
TABLE 85 GLOBAL IN VITRO DIAGNOSTICS MARKET SALES AND FORECAST
THROUGH 2018 ($ MILLIONS) 181
TABLE 86 CANCER TESTING MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 183
TABLE 87 KEY PLAYERS 184
TABLE 88 SIGNIFICANT DEVELOPMENTS IN CANCER FOLLOW-UP 187
TABLE 89 CANCER TESTS AND LIMITATIONS - THE CASE AGAINST DEVELOPMENT OF
A UNIVERSAL TEST 188
TABLE 90 GLOBAL BIOMARKER MARKET AND FORECAST, THROUGH 2018 ($
MILLIONS) 188
TABLE 91 THE KEY PLAYERS 189
TABLE 92 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, THROUGH
2018 ($ MILLIONS) 190
TABLE 93 MOLECULAR DIAGNOSTICS MARKET AND FORECAST, THROUGH 2018 ($
MILLIONS) 191
TABLE 94 CTC'S - DIFFERENTIATING FEATURES 194
TABLE 95 STEM CELL MARKET OVERVIEW 196
TABLE 96 KEY COMPANIES SELLING STEM CELL RESEARCH PRODUCTS 196
TABLE 97 CTC COMPANIES WITH PROMISING PRODUCTS 197
TABLE 98 CLINICAL USE OF CELLSEARCH SYSTEM 198
TABLE 99 PRICING (DOLLARS) 199
TABLE 100 CELLSEARCH KIT 199
TABLE 101 GLOBAL CIRCULATING TUMOR CELL TESTING MARKET SALES AND
FORECAST BY REGION, THROUGH 2018 ($ MILLIONS) 201
TABLE 102 GLOBAL CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER -
SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS) 202
TABLE 103 GLOBAL CIRCULATING TUMOR CELL MARKET FOR BREAST CANCER -
SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS) 204
TABLE 104 GLOBAL CIRCULATING TUMOR CELL MARKET FOR COLORECTAL CANCER
- SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS) 205
TABLE 105 U.S. CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER -
SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 207
TABLE 106 U.S. CIRCULATING TUMOR CELL MARKET - BY INDICATION, SALES AND
FORECAST, THROUGH 2018 ($ MILLIONS) 208
TABLE 107 EUROPEAN CIRCULATING TUMOR CELL MARKET SALES AND FORECAST,
THROUGH 2018 ($ MILLIONS) 209
TABLE 108 EUROPEAN CIRCULATING TUMOR CELL MARKET BY CANCER TYPE -
SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 210
TABLE 109 REST OF WORLD CIRCULATING TUMOR CELL MARKET SALES AND
FORECAST, THROUGH 2018 ($ MILLIONS) 210
TABLE 110 REST OF WORLD CIRCULATING TUMOR CELL MARKET BY CANCER TYPE -
SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 212
TABLE 111 CIRCULATING TUMOR CELL ASSAY CHARACTERISTICS 216
TABLE 112 CTC PATENTS 217
TABLE 113 KEY PATENTS BY AVIVA BIOSCIENCES 221
TABLE 114 COMMERCIAL CIRCULATING TUMOR CELL TECHNOLOGY PLATFORMS 226

LIST OF FIGURES

SUMMARY FIGURE GLOBAL MARKET SALES AND FORECAST FOR CIRCULATING
TUMOR CELL TECHNOLOGY, 2012-2018 ($ MILLIONS) 8
FIGURE 1 GLOBAL CANCER INCIDENCE ESTIMATES, 2008 AND 2030 (MILLIONS) 37
FIGURE 2 UNITED STATES - COMMON TYPE OF CANCER ESTIMATES, 2013 50
FIGURE 3 UNITED STATES - COLORECTAL CANCER INCIDENCE ESTIMATES, 2013 56
FIGURE 4 PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008
(THOUSANDS) 58
FIGURE 5 GLOBAL ESTIMATED PROSTATE CANCER DEATHS AND
AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008 61
FIGURE 6 GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER 2008-2030
(NUMBER) 62
FIGURE 7 PROSTATE CANCER CASES AND DEATHS IN THE U.S., 2008-2011 (NUMBER) 63
FIGURE 8 ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012-2030
(NUMBER) 64
FIGURE 9 ESTIMATED PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030
(NUMBER) 66
FIGURE 10 EUROPEAN (EU27 COUNTRIES) ESTIMATED PROSTATE CANCER

MORTALITY - AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS,
2008
68
FIGURE 11 PROSTATE CANCER DEATHS IN THE U.K., 2010 (RATE PER 100,000
POPULATION) 71
FIGURE 12 TUMOR TYPES - PROJECTED NEW CASES AND ESTIMATED DEATHS, 2010 113
FIGURE 13 GLOBAL CANCER INCIDENCE - ESTIMATES, 2008-2030 (MILLIONS) 167
FIGURE 14 GLOBAL CANCER SURVIVORS 2008 (MILLIONS) 169
FIGURE 15 GLOBAL CANCER DRUG MARKET SALES AND FORECAST, 2012-2018 ($
MILLIONS) 173
FIGURE 16 GLOBAL IN VITRO DIAGNOSTICS MARKET SALES AND FORECAST
2012-2018 ($ MILLIONS) 181
FIGURE 17 CANCER TESTING MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 183
FIGURE 18 GLOBAL BIOMARKER MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 188
FIGURE 19 U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, 2012-2018
($ MILLIONS) 190
FIGURE 20 MOLECULAR DIAGNOSTICS MARKET AND FORECAST, 2012-2018 ($
MILLIONS) 191
FIGURE 21 GLOBAL CIRCULATING TUMOR CELL TESTING MARKET SALES AND
FORECAST BY REGION, 2012-2018 ($ MILLIONS) 201
FIGURE 22 GLOBAL CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER -
SALES AND FORECAST BY REGION, 2012-2018 ($ MILLIONS) 203
FIGURE 23 GLOBAL CIRCULATING TUMOR CELL MARKET FOR BREAST CANCER -
SALES AND FORECAST BY REGION, 2012-2018 ($ MILLIONS) 204

FIGURE 24 GLOBAL CIRCULATING TUMOR CELL MARKET FOR COLORECTAL CANCER
-SALES AND FORECAST BY REGION, 2012-2018 ($ MILLIONS) 205
FIGURE 25 U.S. CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER -
SALES AND FORECAST, 2012-2018 ($ MILLIONS) 207
FIGURE 26 U.S. CIRCULATING TUMOR CELL MARKET - BY INDICATION SALES AND
FORECAST, 2012-2018 ($ MILLIONS) 208
FIGURE 27 EUROPEAN CIRCULATING TUMOR CELL MARKET SALES AND FORECAST,
2012-2018 ($ MILLIONS) 209
FIGURE 28 REST OF WORLD CIRCULATING TUMOR CELL MARKET SALES AND
FORECAST, 2012-2018 ($ MILLIONS) 211
FIGURE 29 REST OF WORLD CIRCULATING TUMOR CELL MARKET BY CANCER TYPE -
SALES AND FORECAST, 2012-2018 ($ MILLIONS) 212

To order this report: Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global Markets
http://www.reportlinker.com/p02009162/Circulating-Tumor-Cell-CTC-Diagnostics-Technologies-and-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.